The pharmacological treatment of urinary incontinence

Andersson,; Appell,; Cardozo,; Chapple, Christopher R.; Drutz,; Finkbeiner,; Haab,; Navarrete, Vela

doi:10.1046/j.1464-410x.1999.00397.x

Cited by 219 publications

(201 citation statements)

References 299 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…Botulinum neurotoxin type A (BoNT/A) injections into the detrusor muscle is a recommended therapy for neurogenic detrusor overactivity (NDO), when antimuscarinic drug therapy failed or is not tolerated [1][2][3][4]. BoNT/A injections have been successfully used to treat NDO worldwide and further indications and therapy options are currently explored [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging

et al. 2009

View full text Add to dashboard Cite

OBJECTIVES: Although botulinum neurotoxin type A (BoNT/A) intradetrusor injections are a recommended therapy for neurogenic detrusor overactivity (NDO), refractory to antimuscarinic drugs, a standardisation of injection technique is missing. Furthermore, some basic questions are still unanswered, as where the toxin solution exactly spreads after injection. Therefore, we investigated the distribution of the toxin solution after injection into the bladder wall, using magnet resonance imaging (MRI). METHODS: Six patients with NDO were recruited. Three of six patients received 300 U of BoNT/A + contrast agent distributed over 30 injection sites (group 1). The other three patients received 300 U of BoNT/A + contrast agent distributed over 10 injection sites (group 2). Immediately after injection, MRI of the pelvis was performed. The volume of the detrusor and the total volume of contrast medium inside and outside the bladder wall were calculated. RESULTS: In all patients, a small volume (mean 17.6%) was found at the lateral aspects of the bladder dome in the extraperitoneal fat tissue, whereas 82.4% of the injected volume reached the target area (detrusor). In both groups there was a similar distribution of the contrast medium in the target area. A mean of 33.3 and 25.3% of the total detrusor volume was covered in group 1 and 2, respectively. Six weeks after injection, five of six patients were continent and showed no detrusor overactivity in the urodynamic follow-up. No systemic side effects were observed. CONCLUSIONS: Our results provide morphological arguments that the currently used injection techniques are appropriate and safe.A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance Abstract ObjectivesAlthough botulinum neurotoxin type A (BoNT/A) intradetrusor injections are a recommended therapy for neurogenic detrusor overactivity (NDO), refractory to antimuscaric drugs, a standardisation of injection technique is missing. Furthermore, some basic questions are still unanswered, as where the toxin solution exactly spreads after injection. Therefore, we investigated the distribution of the toxin solution after injection into the bladder wall, using magnet resonance imaging (MRI). MethodsSix patients with NDO were recruited. 3 of 6 patients received 300 units of BoNT/A + contrast agent distributed over 30 injection sites (Group 1). The other 3 patients received 300 units of BoNT-A + contrast agent distributed over 10 injection sites (Group 2).Immediately after injection, MRI of the pelvis was performed. The volume of the detrusor and the total volume of contrast medium inside and outside the bladder wall were calculated. ResultsIn all patients, a small volume (mean 17.6%) was found at the lateral aspects of the bladder dome in the extraperitoneal fat tissue, whereas 82.4% of the injected volume reached the target area (detrusor).In both groups there was a similar distribution of the contrast medium in the target area.A mean of 33.3% and 25.3% of th...

show abstract

Section: Introductionmentioning

confidence: 99%

A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Gesetz den Fall, die OAB-Symptomatik verbleibt nach Ausschluß anderweitiger Ursachen als "idiopathisch", gibt es verschiedene Theorien der Ursachen: eine konzentriert sich auf direkt myogene Ursachen (Brading, 1997) (Andersson et al, 2005).…”

Section: Pathologie Und Pathophysiologie Der Oabunclassified

“…Behandlung der OAB ausgegeben (Andersson et al, 2005). Neuere Medikamente dieser Stoffgruppe sind Darifenacin (Hill et al, 2007) und Fesoterodine (Nitti et al, 2007).…”

Section: Medikamentöse Therapieunclassified

Botulinumtoxin in der Urologie

Schulte-Baukloh

Knispel

2004

Urologe [A]

View full text Add to dashboard Cite

“…A committee of experts in incontinence met in July 2001 at the 2nd International Consultation on Incontinence (ICI) in Paris to discuss the principles of treatment of urinary incontinence, including the overactive bladder and polyuria [5]. This committee evaluated the literature on drugs affecting bladder function, particularly those able to increase bladder capacity and reduce storage symptoms.…”

Section: Evaluation Of the Effectiveness Of Treatments For Nocturiamentioning

confidence: 99%

The pharmacological treatment of nocturia

Andersson

2002

BJU International

View full text Add to dashboard Cite

The pharmacological treatment of urinary incontinence

Cited by 219 publications

References 299 publications

A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging

A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging

Botulinumtoxin in der Urologie

The pharmacological treatment of nocturia

Contact Info

Product

Resources

About